64results about How to "Improve clinical compliance" patented technology

The invention provides a long acting drug delivery system, which comprises fulvestrant or derivatives thereof and takes phospholipid as a sustained release material. The invention mainly discloses a high concentration formula of fulvestrant or derivatives thereof. The main component is fulvestrant or derivatives thereof. The sustained release material is different phospholipids or a mixture of phospholipids and different kinds of plant oil. The solvent is at least one of ethanol, ethyl lactate, 1,2-propylene glycol, and ethyl acetate. The analgesic is benzyl alcohol, lidocaine, procaine, or ropivacaine. The viscosity of the formula is 20-45 mPa.s, and the concentration of the formula is 60-300 mg/mL. The antioxidant of the formula is Ve, lipoic acid, and the like. The phospholipids can increase mutual solubility and has a sustained release function. The preparation is prepared in an aseptic filtration mode.

The invention discloses a bullatacin ethosome gel and a preparation method thereof. The bullatacin ethosome gel comprises ethosomes and a gel, wherein the ethosomes and the gel exit in a uniformly mixed state; the ethosomes are particles containing bullatacin, phospholipids, low-molecular weight alcohols, cholesterol, stabilizers, antioxidants and water; the particle size of the ethosomes ranges from 30 nm to 400 nm; the gel contains a gel matrix, penetration enhancers, humectant, antiseptics, pH regulators and water; and the ethosomes and the gel are combined at a certain weight ratio, and the ethosomes and the gel have specific compositions respectively. The bullatacin ethosome gel provided by the invention can reduce irritation to the skin and has good percutaneous penetration effects.

The invention relates to a long-acting fulvestrant or fulvestrant derivative sustained release preparation and preparation method of the long-acting fulvestrant or fulvestrant derivative sustained release preparation. The formula of the preparation provided by the invention comprises (1) 10mg/ml to 500mg/ml fulvestrant or fulvestrant derivative served as the active compound based on the content of preparation, (2) 3% to 80% of ketone compound or dimethyl sulfoxide served as the cosolvent based on the total weight of the preparation, (3) dispersing agent using vegetable oil or synthetic grease (ester), (4) analgesic, and (5) optional antioxidant.

The invention provides a GLP-1 (glucagon-like peptide-1) analogue modified with PEG (polyethylene glycol). The GLP-1analogue has an amino acid sequence shown in SEQ ID NO: 1-19, and the cysteine residue of the amino acid sequence is modified with a PEG group. The invention further provides an application of the analogue or analogue composition in preparation of drugs for treating diabetes, obesity and Alzheimer's disease. The polypeptide has better metabolism stability, has remarkably prolonged in-vivo half-life period, solves the problem that the half-life period of natural GLP-1 is short, can substantially improve the clinical application compliance and has higher application value.

The present invention provides a precursor polypeptide or a pharmaceutically acceptable salt of a glucagon-like peptide-1 analogue, wherein the precursor polypeptide has an amino acid sequence represented by the following general formula I HX1X2GTFTSDVSSYLEEX3AAX4EFIX5WLVKX6X7X8X9, and X1, X2, X3, X4, X5, X6, X7, X8 and X9 represent arbitrary amino acids. The present invention further provides a glucagon-like peptide-1 analog or a pharmaceutically acceptable salt thereof. According to the present invention, the glucagon-like peptide-1 analog is obtained by conjugating a polypeptide optimized based on an endogenous GLP-1 (7-36/37) sequence and polyethylene glycol having a specific structure, has strong blood glucose lowering activity so as to reduce the dosage, and has significantly-prolonged half-life in vivo so as to be expected to improve clinical compliance; and the precursor polypeptide and the endogenous GLP-1 (7-36/37) are highly homologous in the sequence so as to reduce the immunogenicity, such that the precursor polypeptide has good potential in the drug development application.

The invention provides a long-acting glucagon-like peptide-1 analogue. The long-acting glucagon-like peptide-1 analogue is characterized in that the polypeptide has a structure shown as a general formula I: Z1-HX8EX10T FTSDV SSYLE X22QAAK EFIX30W LVKX35RG-Z2, wherein, any two residues of X8, X10, X22, X30, X35 are cysteine, Z2 is -H or -HN2; any one residue of X8, X10, X22, X30, X35 is cysteine, and Z2 is a -CG sequence. The glucagon-like peptide-1 analogue expressed by the general formula I always contains two cysteine residues to form an intramolecular disulfide bond, so that rapid degradation of the analogue in vivo is avoided, and the in-vivo half life is obviously prolonged.

The invention provides a tetrodotoxin enteric-coated and sustained-release pellet and a preparation method thereof, and relates to the field of a medicine preparation technology and application. The tetrodotoxin enteric-coated and sustained-release pellet sequentially comprises a blank pellet core, an upper medicine layer, a sustained-release layer, an isolation layer and an enteric layer from inside to outside, wherein the upper medicine layer is tetrodotoxin containing a cosolvent and a bonding agent; according to a weight ratio, the weight of the sustained-release layer accounts for 20 percent to 40 percent of the weight of the medicine containing pellet; the weight of the isolation layer accounts for 2 percent to 8 percent of the weight of the sustained-release pellet; the weight of the enteric layer accounts for 10 percent to 30 percent of the weight of the isolation pellet. The blank pellet core is used as a medicine carrier; a fluidized bed medication method is used for preparing the tetrodotoxin medicine-carried pellet; the sustained-release layer, the isolation layer and the enteric layer are sequentially sprayed to obtain the tetrodotoxin enteric-coated and sustained-release pellet. The advantages of medicine release controllability, a long-period pain relieving effect, good clinic use complaisance, high safety and the like are realized. In addition, the blank pellet core fluidized bed medication and coating method is applicable to the preparation of the ultra-low-specification tetrodotoxin medicine oral sustained-release preparation; the medication rate is high; the content uniformity is good.

The invention relates to a stable Montelukast oral film preparation. The oral film preparation contains an effective amount of Montelukast or pharmaceutically acceptable salts of the Montelukast, a drug stabilizer at least comprising edetic acid and/or editate as well as pharmaceutically acceptable auxiliary materials. The Montelukast oral film preparation obtained according to the formula is accurate in dose, stable in quality and capable of effectively preventing oxidization and degradation of effective components, has the advantages of bright color, good taste, capability of being quickly dissolved in an oral cavity without water, improves the administration compliance of a patient and is particularly suitable for infants and patients suffering from dysphagia.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a dexibuprofen injection and a preparation method thereof. The dexibuprofen injection per ml comprises 10-90 mg of dexibuprofen. The high temperature resistance and hard light tolerance of a dexibuprofen injection prepared according to the invention are obviously superior to those in the prior art, the product stability is better, the quality is better, the requirements of clinical intravenous drip can be satisfied, and the clinical compliance is better.

The invention discloses a preparation method of painted medicinal carbon film-coating tablet produced by the raw material of medicinal carbon and medicinal excipients. The invention is characterized in that painted medicinal carbon film coating tablets are produced in the preparation method, thus the visual defect of black medicinal carbon is overcome and the painted tablets are easy to be accepted by patients. The smooth and round form of the painted medicinal carbon film coating tablet can help effectively guarantee the tablet quality and improve the clinical compliance of patients.

The invention provides an esomeprazole magnesium suspension tablet which is prepared by mixing and tabletting an esomeprazole pill, a filler, corrigent, a disintegrating agent, a suspending agent, a lubricant and the like, wherein the esomeprazole pill is prepared by carrying the medicine in a pill core, wrapping an isolating layer and wrapping an enteric coating. Because of nicking, the esomeprazole magnesium suspension tablet can be torn apart for taking; a small pill tabletting process is adopted, the divided dose is accurate, the enteric effect of the pill is not affected after the tablet is torn apart, the tablet can be reasonably taken according to the age and the weight of children, and the clinical compliance is improved. The esomeprazole magnesium suspension tablet provided by the invention can be rapidly dispersed into suspension, is beneficial for distribution of the medicine in gastrointestinal tracts, can improve the bioavailability of the medicine, and is also applicable to patients with dysphagia.

The invention belongs to the technical field of urinary science, and particularly relates to a compound preparation for treating erectile dysfunction, a compound preparation for treating erectile dysfunction and a solvent coating method for preparing the compound preparation. The effective medicine component of the compound preparation are a compound preparation sublingual membrane of sildenafil citrate and aspirin, and the compound preparation further comprises a disintegrating agent, a humectant, a stabilizer, a film forming material and a plasticizer, wherein the mass ratio of the sildenafil citrate to the aspirin is 1:(0.1-0.9). The sildenafil citrate in the compound preparation sublingual membrane is quick to disintegrate and high in bioavailability, gastrointestinal tract damage andliver first-pass effect can be avoided, toxic and side effects are reduced, sudden death caused by coronary heart disease and the like after sildenafil is taken is prevented, the side effects are greatly reduced, and a synergistic interaction effect is achieved. The compound preparation not only can improve the clinical use compliance of existing marketed dosage forms, but also can improve the clinical curative effect, and has particularly high clinical development and use values.

The invention discloses a sodium rabeprazole medicinal composite, which contains the active substances of sodium rabeprazole and stabilizing agent, wherein the weight ratio of the stabilizing agent and the sodium rabeprazole is 0.05-10/1, and the sodium rabeprazole medicinal composite also contains other optional pharmaceutically acceptable additives. The composite uses less amount of the stabilizing agent, has good stability and a simple preparing technology.

The invention relates to polyethylene glycol electrolyte oral liquid and belongs to the field of medicine. The polyethylene glycol electrolyte oral liquid comprises polyethylene glycol, sodium bicarbonate, sodium chloride and potassium chloride. The polyethylene glycol electrolyte oral liquid has the advantages that the oral liquid is a solution and does not contain any preservative, patients can take the oral liquid directly without preparation, and the oral liquid is convenient to take and safe; the oral liquid is a concentrated preparation, required dosage is small, only 25 mL of the oral liquid is required for treating constipation, 50 mL is required for gut purge, adverse reaction like nausea and abdominal distension are avoided, and patient compliance is high.

The invention provides a propranolol hydrochloride gel preparation for external use and a preparation method and application thereof. The propranolol hydrochloride gel preparation for the external use contains at least 3% by weight of propranolol hydrochloride. The propranolol hydrochloride gel preparation for the external use has good stability and skin permeability and has a significant curative effect on treatment and prevention of infantile hemangioma located in different subcutaneous depths.

The invention belongs to the technical field of traditional Chinese medicine preparation, and particularly relates to a traditional Chinese medicine composition capable of resisting helicobacter pylori and an application. The traditional Chinese medicine composition is improved on the basis of famous Zuojin pills and Xianglian pills and comprises a rhizoma coptidis extract, a fructus evodiae and coptis chinensis extract, and a cortex phellodendri extract, wherein the content of berberine is greater than 50%, the effect of resisting the helicobacter pylori is good, besides, through the combination with the fructus evodiae and costus roots, the side effects of the product are effectively eliminated, and the safety of the medicine is improved; the traditional Chinese medicine composition is used in combination with a clinical standard therapy (triple therapy) for treating HP, so that the curative effect can be further improved, and intestinal flora disorder caused by the triple therapy and toxic and side effects of the triple therapy can be repaired.

The invention relates to ciclosporin medicine composition of injection drug administration, comprising ciclosporin which serves as an active ingredient, Carmowax15-hydroxystearate (solutol HS 15) which serves as a solubilizer, alcohols or esters which serve as latent solvent and water for injection which serves as solvent. The medicine composition can be prepared into injecta or lyophilized preparation. The medicine composition of the invention not only solves the problem that severe anaphylactic reaction exists as the existing ciclosporin injecta contains much Cremophor EL, but also prevents severe anaphylactic reaction from occurring and causes little acrimony; the medicine composition also solves the problem that the previous technology can not solve the stability and solubility of the ciclosporin injecta and avoids the insufficiencies of complex preparation technique and low cost caused by the adoption of technologies such as nanometer technology and lipidosome technology; the medicine composition further solves the technical problem of the stability and solubility of lyophilized powder injecta, which can not be solved by the previous technology, as a result, the medicine composition features good stability and solubility; the preparation technique of the injecta is simple, the quality control is simple and convenient, the production cost is relatively low, thus greatly reducing economic burden of the patients in terms of medicine use.

A lipid composition of vincristine sulfate in the form freeze dried powder for intravenous injection or drip is prepared from the vincristine sulfate, phosphatide and cholesterin.

The invention discloses an externally applied traditional Chinese medicine composition for treating gynecological diseases. The composition comprises the following traditional Chinese medicine components: cortex acanthopanacis, obscured homalomena rhizome, garden balsam stem, notopterygium root, radix angelicae pubescentis, daemonorops draco, frankincense, myrrh, safflower, folium artemisiae argyi, parasitic loranthus, teasel root, rhizoma sparganii, curcuma zedoary, radix paeoniae rubra, pericarpium zanthoxyli, dandelions, radix angelicae dahuricae and radix saposhnikoviae. A preparation method of a transdermal medicine delivery patch prepared from the traditional Chinese medicine components comprises the steps of preparing superfine medicine powder and preparing the patch. Besides, the invention further discloses application steps of the transdermal medicine delivery patch to treatment of gynecological diseases. The traditional Chinese medicine composition provided by the invention has a good curative effect and few side effects; According to the transdermal medicine delivery patch prepared from the traditional Chinese medicine composition, by means of an ultrasonic introductiontechnology, effective components in medicines permeate into deep tissues through local skin, so that relatively high medicine concentration is rapidly achieved, and the purpose of treatment is furtherachieved. A transdermal medicine delivery technology is good in directionality, accurate and controllable in action range, high in treatment efficiency, small in local irritation and good in clinicalcompliance.

The invention relates to a recombinant human endostatin nanoparticle composition for injection and a preparation method thereof. The recombinant human endostatin nanoparticle composition can be prepared by methods such as a covalent bond linking method and an ionic induction method and by using biologically degradable polymer as a carrier. The recombinant human endostatin nanoparticle composition can be prepared into injection and freeze-dried powder injection, has high medicament carrying capacity and uniform particle size distribution, is suitable for intravenous injection and can delay the release of recombinant human endostatin.

The invention belongs to the technical field of medicines and discloses a cyclosporine A and amphiphilic hyaluronic acid derivative composition and a preparation method thereof. The composition is prepared from cyclosporine A and the amphiphilic hyaluronic acid derivative. The composition has the characteristics of high medicine loading capacity, good stability and good biocompatibility and can overcome such defects of the ophthalmic cyclosporine preparations as lower bioavailability and toxic and side effects. The preparation method is simple and is convenient to use.

The invention discloses a Chinese medicine composition for preventing and treating hyperuricemia and hyperlipemia and a preparation method thereof, and relates to medicine or health-care food for preventing and treating hyperuricemia and hyperlipemia.The Chinese medicine composition for preventing and treating hyperuricemia and hyperlipemia contains extract of a Chinese medicine formula, and according to the formula, the Chinese medicine composition is prepared from, by weight, 3-20 parts of coix seeds, 5-40 parts of glabrous greenbrier rhizome, 3-20 parts of plantain herbs, 1-9 parts of Chinese atractylode rhizome, 1-12 parts of the root of bidentate achyranthes, 1-9 parts of papaw and 1-9 parts of fructus cannabis.The Chinese medicine composition has the functions of clearing away dampness, eliminating water seepage and inducing diuresis for treating stranguria, can obviously regulate and treat the hyperuricemia and hyperlipemia and is free of toxic and side effects after being taken for a long time; the preparation technology is stable, and production feasibility is good.The medicine or health-care food for preventing and treating the hyperuricemia and hyperlipemia contains an effective dose of the Chinese medicine composition for preventing and treating the hyperuricemia and hyperlipemia.

The invention provides glucagon-like peptide-1 (GLP-1) analog monomer peptides. The monomer peptides have the general formula 1: Z1HAX1GTFTSDVSSYLE X2QAAKEFICWLVKGRX3, wherein Z1 is hydrogen, acetyl or trifluoroacetyl; X1 is Met, Leu, Pro, Phe or Tyr; and X2 is Gly, Glu or Aib (2-aminoisobutyric acid). The invention also provides a dimer formed by the monomer peptides, a preparation method of the dimer, and application of the dimer in preparing drugs. The dimer of the GLP-1 analog monomers provided by the invention has the obvious effect of lowering the blood sugar, and the in vivo half life can reach 12-72 hours or above, thereby solving the problem of short half life in the natural GLP-1, and greatly enhancing the clinical application compliance.

The invention relates to the field of pharmaceutical preparation, and discloses a combination of cyclosporine A and alkylation serum albumin and a preparation method thereof. The combination has the characteristics of high drug-loading rate and stability, and can overcome the defects of serious side effects in traditional cyclosporine A preparation and the like. The preparation method has mature process, is simple and suitable for industrialized mass production.